Literature DB >> 22510820

Lipoprotein(a) and homocysteine potentiate the risk of coronary artery disease in male subjects.

Manuel Alfonso Baños-González1, Eduardo Anglés-Cano, Guillermo Cardoso-Saldaña, Marco Antonio Peña-Duque, Marco Antonio Martínez-Ríos, Benjamin Valente-Acosta, Héctor González-Pacheco, Aurora de la Peña-Díaz.   

Abstract

BACKGROUND: Lipoprotein (Lp(a)) and homocysteine (Hcy) are independent risk factors for coronary artery disease (CAD). Hcy promotes the release of free apo(a) from Lp(a). The high fibrin affinity of free apo(a) inhibits plasminogen binding and plasmin generation. Hyperhomocysteinemia can result from a less active variant of methylene tetrahydrofolate reductase (variant C677T). Because the C677T genotype is estimated to be present in 32.2% of the Mexican population, we took advantage of this prevalence to determine the possible potentiating effect between high plasma Lp(a) and Hcy for increasing the risk of CAD in male patients. METHODS AND
RESULTS: First, 222 male patients admitted for coronary angiography were recruited and classified as CAD+ or CAD-. Anthropometric measurements, traditional risk factors, and plasma total Hcy (tHcy) and Lp(a) levels were recorded in both groups. We performed a conditional logistic regression model adjusted for conventional risk factors of CAD and it became clear that Lp(a) ≥30mg/dl was a risk factor for CAD (odds ratio [OR] 5.06, 95% confidence interval [CI] 1.88-13.51, P=0.001), whereas Hcy was not related to CAD (OR 0.44, 95% CI 0.63-2.90, P=0.44). However, when both factors were considered together in an interaction model, high tHcy and high Lp(a) plasma concentrations showed a potentiated effect (OR 10.52, 95% CI 2.18-50.71, P=0.003).
CONCLUSIONS: The combination of high Lp(a) and Hcy levels synergistically increases the likelihood of developing CAD in male patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22510820     DOI: 10.1253/circj.cj-12-0039

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  5 in total

1.  Hyperhomocysteinemia is an independent risk factor in young patients with coronary artery disease in southern China.

Authors:  Y Wu; Y Huang; Y Hu; J Zhong; Z He; W Li; Y Yang; D Xu; S Wu
Journal:  Herz       Date:  2013-02-22       Impact factor: 1.443

2.  Effects of strontium ranelate on markers of cardiovascular risk in postmenopausal osteoporotic women.

Authors:  Marco Atteritano; Antonino Catalano; Domenico Santoro; Antonino Lasco; Salvatore Benvenga
Journal:  Endocrine       Date:  2015-08-25       Impact factor: 3.633

3.  Prognostic Value of Elevated Homocysteine Levels in Korean Patients with Coronary Artery Disease: A Propensity Score Matched Analysis.

Authors:  Sung Woo Kwon; Jong-Youn Kim; Young Ju Suh; Dae Hyung Lee; Young Won Yoon; Byoung Kwon Lee; Young-Hak Jung; Eui-Young Choi; Bum-Kee Hong; Se-Joong Rim; Hyuck Moon Kwon
Journal:  Korean Circ J       Date:  2016-03-21       Impact factor: 3.243

4.  Effects of folic acid supplementation on serum homocysteine and lipoprotein (a) levels during pregnancy.

Authors:  Zohreh Hekmati Azar Mehrabani; Amir Ghorbanihaghjo; Manizheh Sayyah Melli; Maryam Hamzeh-Mivehroud; Nazila Fathi Maroufi; Nasrin Bargahi; Maryam Bannazadeh Amirkhiz; Nadereh Rashtchizadeh
Journal:  Bioimpacts       Date:  2015-12-28

5.  Sortilin and Homocysteine as Potential Biomarkers for Coronary Artery Diseases.

Authors:  Rehab H Werida; Ayman Omran; Noha M El-Khodary
Journal:  Int J Gen Med       Date:  2021-09-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.